Investigators determined the feasibility, safety and tolerability of new combinations of tisotumab vedotin (Tivdak; TV) and bevacizumab (Avastin) or pembrolizumab (Keytruda) or carboplatin in a two-part multicohort, phase 1b/2 trial (ENGOT-cx8/GOG-3024/innovaTV 205; NCT03786081). Bradley Monk, MD, FACOG, FACS — associate professor of Obstetrics and Gynecology — presented the dose-binding portion of the study.
About the College
Founded in 2007, the University of Arizona College of Medicine – Phoenix inspires and trains exemplary physicians, scientists and leaders to optimize health and health care in Arizona and beyond. By cultivating collaborative research locally and globally, the college accelerates discovery in a number of critical areas — including cancer, stroke, traumatic brain injury and cardiovascular disease. Championed as a student-centric campus, the college has graduated 593 physicians, all of whom received exceptional training from nine clinical partners and more than 2,400 diverse faculty members. As the anchor to the Phoenix Biomedical Campus, which is projected to have an economic impact of $3.1 billion by 2025, the college prides itself on engaging with the community, fostering education, inclusion, access and advocacy.